Want to see TVRD full AI Analyst Report?
TVRD Stock Chart & Stats
$1.82
<$0.01(0.40%)
At close: 4:00 PM EDT
$1.82
<$0.01(0.40%)
Day’s Range― - ―
52-Week Range$0.93 - $43.65
Previous CloseN/A
Volume1.11M
Average Volume (3M)193.16K
Market Cap
$15.21M
Enterprise Value$2.20M
Total Cash (Recent Filing)$15.77M
Total Debt (Recent Filing)$145.00K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 12, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.79
Shares Outstanding13,338,943
10 Day Avg. Volume348,016
30 Day Avg. Volume193,159
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$9.14Price Target Upside402.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 1 Target Engagement And TolerabilityThe Phase 1 results provide clinical proof-of-mechanism for TTI-109, with pharmacokinetic exposure above the STAT3 IC₅₀ and reductions in relevant immune-cell populations. Improved tolerability may support adherence and strengthen the candidate’s prospects for later-stage development.
Expansion Into Ulcerative ColitisSelecting ulcerative colitis gives the lead program a defined development path in a large, underserved market and focuses resources on a specific unmet need. An oral, tissue-targeted STAT3 approach could differentiate TTI-109 from single-pathway therapies if later studies confirm meaningful clinical benefit.
Low Current Debt BurdenMinimal current debt reduces interest obligations and avoids the immediate balance-sheet pressure associated with substantial borrowing. This gives Tvardi more flexibility to direct available capital toward clinical development, although the benefit is limited by declining assets and the company’s need for external funding.
Bears Say
No Current Revenue And Persistent LossesThe absence of current revenue means Tvardi has not yet established a commercial funding engine and remains dependent on development financing. Persistent net and operating losses reduce financial resilience, making future progress reliant on successful clinical execution and eventual product monetization.
Ongoing Cash BurnSustained negative operating and free cash flow shows that losses are translating into substantial cash consumption rather than mainly non-cash charges. Continued burn will require additional financing to maintain research and clinical programs, limiting flexibility and increasing funding risk over the coming periods.
Dependence On Equity FinancingExpanding the at-the-market program provides funding capacity but also highlights Tvardi’s reliance on issuing equity to support operations. Further share issuance can dilute existing holders and may become an ongoing constraint while the company has no revenue and continues to fund clinical development.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $0.93 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $15.21M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 36 days.
How were Tvardi Therapeutics’s earnings last quarter?
Tvardi Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.704 by $0.014.
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 13,338,943 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Tvardi Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.704. Following the earnings report the stock price went up 7.345%.
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
TVRD Stock 12 Month Forecast
Average Price Target
$9.14
▲(402.35% Upside)
Technical Analysis
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
3.36%
Insiders
5.61% Mutual Funds
8.34% Other Institutional Investors
80.10% Public Companies and
Individual Investors